CTOs on the Move

NxStage Medical

www.nxstage.com

 
NxStage System One dialysis machines offer the comfort and flexibility of hemodialysis at home. Discover how our products can improve your quality of life.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.nxstage.com
  • 350, Merrimack Street
    Lawrence, MA USA 01843
  • Phone: 978.687.4700

Executives

Name Title Contact Details

Similar Companies

Eisai

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Schmidt and Sons Pharmacy Inc

Schmidt and Sons Pharmacy Inc is a Tecumseh, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeon Biopharma

Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.

America's Assisted Living Pharmacy

America's Assisted Living Pharmacy, Inc. is a Paducah, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allarity Therapeutics

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.